Drugs / IPV SSI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT02280447 Comparator | Nov 2014 → Mar 2015 | — | Statens Serum Institut | Completed | Missed primary |
| Phase 3 | NCT03032419 Comparator | Feb → Sep 2017 | poliomyelitis | Statens Serum Institut | Completed | Met primary |
| Phase 3 | NCT03025750 Comparator | Jan → Nov 2017 | poliomyelitis | Statens Serum Institut | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPV SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03032419 ↗ |
| Known as | IPV Vaccine SSI | “compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age” PMID 28027810 ↗ Dec 2016 |
| Modality | Vaccine | “Intramuscular injection of 0.5 mL vaccine into deltoid muscle” NCT02280447 ↗ |
| Route | Intramuscular | “Intramuscular injection of 0.5 mL vaccine into deltoid muscle” NCT02280447 ↗ |